The SARS-CoV-2 worldwide pandemic has presented a significant challenge to business continuity for pharmaceutical manufacturing. It has led to Industry re-assessing the virus control framework, and in particular, any challenges that this may present to the mitigations currently in place. This presentation will focus on the SARS-CoV-2 situation and factors to be assessed in a GMP Biopharmaceutical manufacturing facility and whether they present a secure virus mitigation strategy to protect the product from contamination from this and other viruses.
This copyright notice applies to all proprietary pages, images, text, programs, and other material available throughout this Internet site (collectively, this “Publication”). All materials posted on the website are subject to copyrights owned by the International Society for Pharmaceutical Engineering (“ISPE”) and other individuals or entities. Any reproduction, retransmission or republication of all or part of any documents found on this site is expressly prohibited, unless ISPE or the copyright owner of the material has expressly granted its prior written consent to reproduce, retransmit or republish the material. All other rights reserved. View entire copyright policy.